- Home
- Products
- Customized FluoroAb™
- EDNRB
- Anti-EDNRB MAb (Clone 2)-iFluor® 514 Succinimidyl Ester
Anti-EDNRB MAb (Clone 2)-iFluor® 514 Succinimidyl Ester (CAT#: WJY0-LS11296)
- TARGET
- ANTIBODY
- DYE
- Name
- EDNRB
- Alternative Names
- EDNRB; Endothelin receptor type B
- Overview
- Anti-EDNRB Antibody (Clone 2)
- Species Reactivity
- Human
- Name
- iFluor® 514 Succinimidyl Ester
- Color
- Green
- Excitation⁄Emission (nm)
- 511/527
- Detection method
- Fluorescent
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for WJY0-LS11296. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
| CAT# | Product Name | Linker | Payload |
| ADC-W-601 | Anti-EDNBR-VC-MMAE ADC-1 | VC (valine-citrulline) | MMAE (Monomethyl auristatin E) |
| ADC-W-565 | Anti-EDNRB-VC-MMAE ADC | VC (valine-citrulline) | MMAE (Monomethyl auristatin E) |
| ADC-W-536 | Anti-EDNRB (endothelin B)-VC-MMAE ADC | VC (valine-citrulline) | MMAE (Monomethyl auristatin E) |
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-STEAP MAb (Clone 3)-iFluor® 450 Succinimidyl Ester (CAT#: WJY0-LS7109)
- Anti-TNFRSF8 MAb (Clone 18)-iFluor® 350 Succinimidyl Ester (CAT#: WJY0-LS712)
- Anti-IL12+IL23 MAb (Clone 2)-iFluor® 440 Succinimidyl Ester (CAT#: WJY0-LS5346)
- Anti-CD19 MAb (Clone 5)-iFluor® 460 Succinimidyl Ester (CAT#: WJY0-LS8090)
- Anti-CD2 MAb (Clone 18)-iFluor® 405 Succinimidyl Ester (CAT#: WJY0-LS2653)
- Otlertuzumab-iFluor 568 (CAT#: ADC-FL-511)
- Anti-EDA MAb (Clone 5)-iFluor® 514 Succinimidyl Ester (CAT#: WJY0-LS11754)
- Anti-FGFR2 MAb (Clone 8)-iFluor® 405 Succinimidyl Ester (CAT#: WJY0-LS1796)
- Anti-IL9 MAb (Clone 2)-iFluor® 532 Succinimidyl Ester (CAT#: WJY0-LS12947)
- Anti-PCSK9 MAb (Clone 6)-iFluor® 405 Succinimidyl Ester (CAT#: WJY0-LS2980)
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
